Form 4: BioCryst Pharmaceuticals Director Sells Shares to Cover Tax Obligations

Amy E. McKee, a director at BioCryst Pharmaceuticals, sold 8,600 shares of common stock on June 24, 2024, to cover tax liabilities related to the vesting of restricted stock units.

Summary

• On June 24, 2024, Amy E. McKee, a director of BioCryst Pharmaceuticals, sold 8,600 shares of the company's common stock.
• The sale was executed to cover the tax liability incurred from the vesting of 16,745 Restricted Stock Units on June 13, 2024.
• The shares were sold at a weighted average price of $6.32, with individual transactions ranging from $6.25 to $6.42.
• Following the transaction, McKee directly owns 27,831 shares of BioCryst Pharmaceuticals.
• The reporting person will provide full information regarding the number of shares sold at each price within the range set forth in this footnote upon request.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares to cover tax obligations) and does not contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales of shares by company directors are a common occurrence, often related to personal financial planning or tax obligations. The sale itself is unlikely to have a significant impact on the company's overall performance or stock valuation.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder perception, but is unlikely to significantly affect other stakeholders.

Key Dates